Primary Disease
8
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
12.5%
1 terminated out of 8 trials
87.5%
+1.0% vs benchmark
25%
2 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis
Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling
Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking